Financial Architects, Inc Blueprint Medicines Corp Transaction History

Financial Architects, Inc

  • $657 Million
  • Q2 2023

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 01, 2019
SELL
$45.57 - $74.26 $104,811 - $170,798
-2,300 Closed
0 $0
Q3 2018

Oct 29, 2018
SELL
$58.91 - $78.32 $42,238 - $56,155
-717 Reduced 23.77%
2,300 $180,000
Q1 2018

Apr 23, 2018
BUY
$73.28 - $102.95 $221,085 - $310,600
3,017 New
3,017 $277,000

Others Institutions Holding BPMC

# of Institutions
350
Shares Held
60.3M
Call Options Held
2.25M
Put Options Held
1.18M
View Full List

About Blueprint Medicines Corp

BPMC Quotes by TradingView
  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.62B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Financial Architects, Inc Portfolio

Follow Financial Architects, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Financial Architects, Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email